Omega-3 and depression
This article was originally published in The Tan Sheet
Although results of a meta-analysis shows omega-3 polyunsaturated fatty acids demonstrate a significant antidepressant efficacy, the finding cannot be validated due to publication bias and heterogeneity, according to authors of the meta-analysis published in the July Journal of Clinical Psychology. The research was based on 10 double-blind, placebo-controlled studies in patients with mood disorders receiving omega-3 PUFAs with the treatment period lasting four weeks or longer. "More large-scale, well-controlled studies are warranted to find out the favorable target subjects, the optimal composition and the dosage of EPA and DHA, and the long-term efficacy of omega-3 fatty acids in treating depression," say Pao-Yen Lin, Department of Psychiatry, Change Gung Memorial Hospital-Kaohsiung Medical Center, Taiwan, et al...
You may also be interested in...
Most clinical trial sponsors view data disclosure as a mandate, maintaining regulatory compliance as a legal requirement. Study sponsors that realize the potential to repurpose this data, using a patient-first approach, turn transparency into a strategic advantage for engagement and recruitment efforts.
The Bio-Console 560 extracorporeal blood pumping console is being recalled over reports it could lose power during bypass surgery, which could lead to organ or neural dysfunction, blood clots, or even death.
House passes “SAFE Banking” Act sponsored by Rep. Ed Perlmutter to allow cannabis- and hemp-related businesses in states with some form of legalized marijuana to access financial services by creating protections for those institutions. Sen. Jeff Merkley introduced the same legislation in March.